NITROXIDE LABELED HEMOGLOBIN AS A BLOOD SUBSTITUTE

一些生物制药公司已经成功地采取了 以血红蛋白为基础的氧气载体(HBOC)进入I期临床试验。 然而，输血一直被限制在低剂量水平。 由于观察到的高血压和血管收缩作用 临床前动物研究中的剂量水平。这项建议涉及 由于目前的HBOC未能进行氧化解毒 类似于红血球固有的系统 打算用来替代。这项研究计划打算修改一种高- 目前正在进行临床试验的优质HBOC，以证明 稳定的氮氧化物自由基可以用来进行 抗氧化解毒功能。如果研究成功， 然后，为第二代红血奠定了基础 可以成功商业化的细胞替代品。

A number of biopharmaceutical companies have successfully taken hemoglobin-based oxygen carriers (HBOC) into phase I clinical trial. However, transfusions have been limited to low dosage levels due to observed hypertensive and vasoconstrictive effects at high dosage levels in pre- c1inical animal studies. This proposal deals with the current HBOC's failure to have an oxidant detoxification system similar to the one which is intrinsic to the red blood cells it intends to substitute. This research plan intends to modify a high- quality HBOC, which is currently in clinical trials, to demonstrate that stable nitroxide free radicals can be used to perform an oxidant detoxification function. If the research is successful, then the groundwork would established for a second generation red blood cell substitute which could successfully commercialized.